SCHEMBL23327491

SCHEMBL23327491

COc1ccc(CN(C)c2cc(Cl)nc3c(NC(=O)NCCc4cccc(N)c4)cnn23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 4/20 0.46
▸ KMT2A Q03164 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ CNR1 P21554 2/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ FPR2 P25090 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ ROCK2 O75116 1/20 0.37
▸ ROCK1 Q13464 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ PKM P14618 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ NOX4 Q9NPH5 1/20 0.36
▸ CA12 O43570 2/20 0.36
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA5A P35218 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29930766 0.90 LMNA (0.42) TRPV1KMT2AMEN1ALDH1A1KDM4E
SCHEMBL23327453 0.90 LMNA (0.42) TRPV1KMT2AMEN1ALDH1A1KDM4E
SCHEMBL23351083 0.86 LMNA (0.47) TRPV1KMT2ACNR1MAPK1FPR2
SCHEMBL23327703 0.83 KDM4E (0.36) TRPV1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL23327537 0.82 NR3C2 (0.38) KMT2AMEN1NPC1SMN1; SMN2HTT
SCHEMBL23327500 0.77 ALDH1A1 (0.43) KMT2ANPC1RAB9ASMN1; SMN2HTT
SCHEMBL23351205 0.76 ALDH1A1 (0.35) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL26098304 0.74 PTPN1 (0.49) KMT2AMEN1SMN1; SMN2HTTALDH1A1
SCHEMBL21811192 0.70 KDM4E (0.44) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL23327454 0.69 MAPT (0.42) NPC1MAPK1ALDH1A1RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348478-A1 TYK2 PSEUDOKINASE LIGANDS VENTYX BIOSCIENCES, INC. 2023-11-02 — — US disclosed
US-11753411-B2 Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands VENTYX BIOSCIENCES, INC. (US) 2023-09-12 — — US disclosed
EP-4054581-A1 TYK2 PSEUDOKINASE LIGANDS Ventyx Biosciences, Inc. (US) 2022-09-14 — — EP disclosed
US-20210139486-A1 TYK2 PSEUDOKINASE LIGANDS VENTYX BIOSCIENCES, INC. 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753411-B2 Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands TYK2, JAK1, JAK2 TRPV1 4454/4885KMT2A 819/4885MEN1 3085/4885
US-20230348478-A1 TYK2 PSEUDOKINASE LIGANDS TYK2, JAK2, PTK2B TRPV1 4340/4885KMT2A 901/4885MEN1 3354/4885
US-20210139486-A1 TYK2 PSEUDOKINASE LIGANDS TYK2, JAK2, PTK2B TRPV1 4340/4885KMT2A 901/4885MEN1 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback